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Abstract
A severely immune-suppressed AIDS patient was suspected of suffering from BK virus (BKV)
meningoencephalitis, after being studied for common causes of neurological complications of co-
infectious origin. Polymerase chain reaction (PCR) and sequence analysis of cerebrospinal fluid and
brain samples, confirmed the presence of BKV. His clinical condition improved along with the
regression of brain lesions, after modifications on his antiretroviral regime. Five months after
discharge, the patient was readmitted because of frequent headaches, and a marked inflammatory
reaction was evidenced by a new magnetic resonance imaging (MRI). The symptoms paralleled a
rising CD4+ lymphocyte count, and immune reconstitution syndrome was suspected. This is the
first non-postmortem report of BKV meningoencephalitis in an AIDS patient, showing clinical and
radiographic improvement solely under HAART.
Background
Neurological complications associated with HIV-1/AIDS
are being recognized with a high frequency that parallels
the increased number of AIDS cases [1]. Since the intro-
duction of HAART, morbidity and mortality secondary to
primary and secondary neurological opportunistic dis-
eases in HIV-1/AIDS patients have significantly decreased
[2,3]. However, neurocognitive impairments continue to
occur in high frequencies, even in countries, with a free
and universal access program to HAART, such as Brazil
[4].
Recently, atypical presentations of brain diseases, such as
JC virus granule cell neuronopathy, and those related to
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the reconstitution of the immune system after initiation
of HAART have been reported in a growing basis [5-7].
These unusual neurological pictures in AIDS patients rep-
resent new diagnostic and therapeutic challenges [7,8].
BKV meningoencephalitis is a rare polyomaviral infection
with fatal outcome when associated with AIDS [9-11]. The
clinical picture is devastating, resulting in death from
multi-organ failure [12]. Here, we describe the clinical
course of an AIDS patient with presumed BKV menin-
goencephalitis who showed substantial improvement
after modification of his HAART regime.
Case presentation
In April 2004, a 43-year-old HIV-1 positive heterosexual
male was admitted to the hospital complaining of bilat-
eral headache of moderate intensity accompanied by
speech, gait and memory disturbances. HIV-1 infection
was diagnosed in July 2003 after an episode of cryptococ-
cal meningitis; with a documented CD4+ lymphocyte
count of 6 cells/mm3. His past medical history includes an
episode of pancreatitis secondary to lopinavir/ritonavir
(July, 2003), and an episode of tuberculous meningitis
(October, 2003). On admission, antiretroviral medica-
tions included zidovudine, lamivudine, and efavirenz
(antiretroviral scheme modified after pancreatitis in
August, 2003). Other medications included: fluconazole,
TMP-SMX, isoniazid, ofloxacin, ethambutol, and pyrazi-
namide (rifampin was discontinued and replaced by
ethambutol and ofloxacin after a marked increased of
hepatic enzymes in November, 2003)
Initial examination revealed mental confusion, dysarthria
and ataxia. Baseline cranial CT scan showed two
hypodense lesions with mass effect and no contrast
enhancement in the left temporo-parietal and right occip-
ito-parietal areas. His CD4+ lymphocyte count was 37
cells/mm3, with an undetectable viral load. Presumptive
cerebral toxoplasmosis was diagnosed, and a treatment
with sulphadiazine-pyrimetamine, folinic acid, and dex-
amethasone was started. After 14 days of therapy, the
patient's neurological status and CT scan findings
remained unchanged. Analysis of the cerebrospinal fluid
(CSF) obtained on day 14 after admission showed 12 leu-
kocytes/mm3 (79% lymphocytes, 10% monocytes), glu-
cose of 46 mg/dl and a protein level of 146 mg/dl. Herpes
simplex encephalitis was suspected, and acyclovir
replaced the medications for toxoplasmosis. After a week
on this therapeutic regime, the patient's neurological sta-
tus remained unaltered, and PCR analysis of CSF was per-
formed, resulting negative for all human herpes viruses,
JCV, and for Toxoplasma gondii. Nevertheless, PCR for
polyomavirus BKV resulted positive.
From this data, acyclovir and dexamethasone were dis-
continued, and the patient underwent MRI-guided stereo-
tactic brain biopsy of the lesion found in the right
occipital lobe. Intraoperative MRI findings were similar to
those previously seen by CT scan (Figure 1A). Histopatho-
logical examination showed thickened leptomeninges
with a lymphocytic infiltrate that extended perivascularly
(Figure 2A). The underlying cortex showed mild astrocy-
tosis with prominent hypertrophic nuclei and bi-nucle-
ated forms (Figure 2A). PCR examination of the brain
tissue sample also showed the presence of BKV DNA in
the absence of any other polyomaviruses (Figure 2C and
2D). The patient was reclassified as with presumptive BKV
subacute meningoencephalitis. His therapeutic regime
included the replacement of efavirenz for atazanavir-
ritonavir along with the administration of zidovudine/
lamivudine, leaving the patient exclusively with HAART.
Urine analysis and renal function tests were performed,
showing <10 leucocytes/field, undetectable red blood
cells and proteins, a serum creatinine of 0.8 mg/dl, and a
BUN of 16 mg/dl. These values, discarded the presence of
renal and urinary abnormalities that are normally present
in the context of BKV clinical infection. Four weeks after
admission, neurological manifestations improved consid-
erably, and the patient was discharged.
Five months after discharge, the patient complained of
mild headaches. A new MRI reported improvement of the
two lesions previously seen; however, new areas of
increased signal intensity of the white matter appeared
(Figure 1B). Based on a rising CD4+ lymphocyte count of
144 cells/mm3, and in the absence of any other co-infec-
tious agent, "encephalopathy of unknown origin" secondary
to immune reconstitution was suspected. We kept close
follow-up without any other intervention, and the patient
gradually recovered.
Seven months after discharge, MRI lesions and CD4+ lym-
phocyte count further improved (Figure 1C.). Since then,
and until May 2007, the patient has been in the same
HAART regime, with no neurological complaints; his
renal and liver function have always been unaltered, and
his last CD4 + lymphocyte count was of 336 cells/mm3
with a viral load bellow 400 copies/ml.
Methods
Serum Hiv-1 viral load detection
All quantifications of viral load were performed by real-
time RT-PCR. The threshold of detection was 400 copies/
ml.
BKV and JCV DNA amplification from CSF samples
PCR technique as described by Arthur et. al.,[13] was used
to amplify the T-antigen gene (173 bp) of both, BKV and
JCV. To establish whether BK viral sequences inhibited the
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reaction, 10 µl of CSF sample were added to duplicate
tubes containing the PCR mixture and polyomavirus
cloned DNA. An amplification band of 173 bp was ana-
lyzed by 2% agarose gel electrophoresis and visualized by
exposure to UV light after staining with ethidium bro-
mide. Discriminating between JCV and BKV was per-
formed by treatment of PCR products (10 µl) with the
restriction enzyme BamH1 (Invitrogen) and analyzed by
electrophoresis on a 3% agarose gel.
BKV and JCV DNA amplification from brain biopsy
DNA was isolated twice from 25 mg of paraffin-embed-
ded tissue using the DNeasy Tissue Kit (QIAGEN, USA).
Negative control of extraction was carried out, using water
instead of lysed tissue sample. DNA amplification was car-
ried out by seminested-PCR on different amount of DNA
purified from paraffin-embedded biopsies. A 150 base
pair fragment of the BKV LT-coding region was amplified
using the outer primers Pep1 and Pep2 and the inner
primers Pep1 and BKS (nt 4513–4529, Dunlop strain).
Parameters for the 30 cycles of outer PCR were 95°C dena-
turation, 54°C annealing and 72°C elongation for 30 sec
A) Representative section of the brain biopsy (H&E 40X) shows thickened leptomeninges with an nfiltrate composed of lym ocytes and plasmocytes that extended perivascularlyFigure 2
A) Representative section of the brain biopsy (H&E 40X) 
shows thickened leptomeninges with an infiltrate composed 
of lymphocytes and plasmocytes that extended perivascu-
larly. Inset shows an astrocyte with prominent and hyper-
chromatic nuclei. B) Electrophoresis on 2% agarose gel of 
BKV PCR products from CSF. Lane 1, Marker 100 bp: Lane 2, 
negative control of PCR; Lane 3, negative control of extrac-
tion; Lane 4, 250 ng DNA; Lane 5, positive control of PCR. 
C) Electrophoresis on 2% agarose gel of JCV PCR products 
from brain biopsy. Lane 1, Marker 100 bp; Lane 2, negative 
control of PCR; Lane 3, negative control of extraction; Lane 
4,1000 ng DNA; Lane 5, positive control of PCR.
Panel A. Intraoperative brain images in April 2004Figure 1
Panel A. Intraoperative brain images in April 2004. An axial 
T1-weighted image after gadolinium injection (left-hand side) 
shows lesions in the gray matter of the left temporo-parietal 
lobe and right occipital lobe (place of biopsy). These images 
show slight enhancement of the lesions particularly in the 
meninges and the presence of mass effect. An axial T2-
weighted image (center) and a FLAIR image (right-hand side) 
show better details of the lesions. Panel B. Brain MRI 
images, 5 months after discharge. Axial T-1 weighted image 
after gadolinium injection (left-hand side) showed important 
improvement in gray matter lesions. However, images in T2-
weighted (center), and FLAIR (right-hand side) showed pres-
ence of new high-signal-intensity lesions in the white matter 
of the right frontal lobe and left occipital lobe. A widening of 
the right ventricle compared to the figure in Panel A can be 
observed. Panel C. Brain MRI images, 7 months after dis-
charge. Axial T-1 weighted image after gadolinium injection 
(left-hand side) shows normal appearance. Images in T2-
weighted (center) and FLAIR (right-hand side) reveal regres-
sion of the white matter changes; however discrete widening 
of the right ventricle is still present.
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each, whereas for the inner PCR the annealing tempera-
ture was 52°C. Urine from a patient with "polyomavirus
associated nephropathy" was used as positive control,
while water as negative control. Amplification of the LT
region of JCV DNA was carried out by nested-PCR on dif-
ferent amount of DNA, by using set of primers JC1 and
JC2 (outer), Pep1 and Pep 2 (inner). Moreover, to discard
contamination by other polyomavirus, we performed a
western blot analysis with the antibody against JCV/SV40
Tag (94 kDa) and against actin (40 kDa) as a control. Our
patient's sample came out negative for the former (data
not shown).
Sequence analysis
PCR products were added to a mixture containing 4 µl of
Ready Reaction Premix 2.5X, 2 µl of BigDye Sequencing
Applied Biosystems 5X buffer, 3.2 pmol of either forward or
reverse primers, and water up to a final volume of 20 µl.
The cycle sequencing was performed using the GeneAmp
PCR System 9700, with the following protocol: initial
denaturation at 96°C for 1', then 25 cycles with a first step
at 96°C for 10", a second step at 50°C for 5" and the last
rapid thermal ramp to 60°C for 4'. 5 µl of the purified
product underwent electrophoresis on an ABI PRISM 310
Genetic Analyzer. Sequence homology searches were per-
formed using BLAST at NCBI (USA).
Conclusion
We report the first in-vivo case of BKV-associated menin-
goencephalitis in an AIDS patient who showed clinical
improvement and regression of brain lesions while on
HAART.
BKV infection is generally a benign condition in immuno-
competent patients, and the causative agent of "polyoma-
virus associated nephropathy" and hemorrhagic cystitis in
immunocompromised individuals [12,14]. However,
there is a growing body of evidence demonstrating its neu-
rotropism [14-16]. Among AIDS patients, only 3 cases of
BKV- meningoencephalitis have been described, and all of
them reported post-mortem [9-12].
Initially, the morphology of the lesions and the cytochem-
ical profile of the CSF samples led us to empirically diag-
nose the patient with cerebral toxoplasmosis and herpes
simplex encephalitis afterwards. However, the lack of
response to treatment and the presence of BKV DNA in
CSF samples and brain tissue led us to reclassify the
patient as with BKV meningoencephalitis.
Compared to the other 3 cases reported, the presence of
BKV DNA in the CSF is a common denominator of true
neurological disease. As previously described, the detec-
tion of BKV genome in brain samples is unspecific, as it is
normally present in 3%–6% of HIV-1 infected patient,
even without neurological symptoms [17]. Our patient's
histopathological description is identical to the ones pre-
viously reported, showing diffuse areas of increased signal
[9,11]. Progressive multifocal leukoencephalopathy was
ruled out because of the normal morphology of oli-
godendrocytes. In terms of the radiological changes, our
case is similar to the previous ones, showing areas of
increased signal intensity of the periventricular white mat-
ter (MRI) [11]. Other descriptions include increased
meningeal contrast enhancement along with increased
meningeal thickness (MRI) [9], and marked internal
hydrocephalus and periventricular lucencies (CT scan)
[10]. None of the previous reports showed features sug-
gesting immune reconstitution inflammatory syndrome
(IRIS).
Our main limitation to conclude that BKV is the causative
agent of the neurological disorders is the lack of demon-
stration of the virus in the brain tissue sample, either by
immunohistochemistry or by in-situ hybridization. Tissue
samples extracted by stereotactic surgery are limited, and
most of the times insufficient to run all diagnostic tests.
These limitations were not faced in other reported cases,
as all of these were done post-mortem.
Another important difference is the lack of renal/systemic
involvement in our patient, when compared to the other
cases previously reported. Our patient' renal work up
included serial urianalysis and renal function tests that
remained normal throughout the course of the disease
(creatinine 0.8 mg/dl, BUN of 16 mg/dl, in April, 2004,
creatinine of 0.9 mg/dl, BUN of 28 mg/dl in October,
2004,). As an outpatient his renal function has continued
in the normal ranges (creatinine of 0.9 mg/dl, BUN of 40
mg/dl, May 2007). The containment of the disease was
possibly related to a partial effect of HAART, similar to
what has been reported for other AIDS-associated neuro-
logical complications in the post-HAART era, opening a
broader spectrum of AIDS-associated neurocognitive dis-
orders [18].
In this case, the change of atazanavir-ritonavir for efa-
virenz might have helped to reactivate the immune sys-
tem, improving the symptoms and morphology of the
lesions associated with BKV meningoencephalitis. The
rationale of this change was based upon our previous
experience and the results of an unpublished work
describing the benefits of protease inhibitors in the resto-
ration of the CD4 count when compared to non-nucleo-
side analogs (Riddler SA, Haubrich R, DiRienzo G, et al. A
prospective, randomized, phase III trial of NRTI-, PI-, and
NNRTI-sparing regimens for initial treatment of HIV-1 infec-
tion: ACTG 5142. Program and abstracts of the XVI Interna-
tional AIDS Conference; August 13–18, 2006; Toronto,
Canada. Abstract THLB0204). Unfortunately, the restora-
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tion of the immune system is not innocuous, and as pre-
viously described, deleterious effects are found in the
context of polyomavirus infection, introduction of
HAART, and a rising CD4+ count [19]. Immune reconsti-
tution inflammatory syndrome (IRIS), as the latter phe-
nomenon is known, affects 15% to 45% of patients
receiving HAART. CNS involvement hás been reported to
occur in the presence of tuberculosis (33%), cryptococco-
sis (4.2%–15.9%), JC vírus (unknown frequency); being
manifested radiologically as the extension or worsening of
a previous condition or by the apparison of lesions that
are enhanced by contrast, with or without involvement of
the meninges and sometimes accompanied by hydro-
cephalus [6]. In our patient, the newly developed cerebral
lesions and the headaches spontaneously resolved.
In conclusion, our report demonstrates that BKV might be
the causative agent of meningoencephalitis in AIDS
patients, and that this virus must be investigated in higher
frequencies in HIV-1 positive patients with neurological
manifestations now that its neurotropism has been better
documented. In our patient, a previously reported life-
threatening and disseminated disease progressed to a
mild and focalized neurological condition in the presence
of HAART.
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